Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed uveal melanoma~* Monosomy 3 status (by fluorescent in situ hybridization \[FISH\] or multiplex ligation-dependent probe amplification \[MLPA\]) or DecisionDx class 2~* Tumor thickness \> 3.0 mm~* Has received definitive treatment of uveal melanoma with brachytherapy, proton therapy, stereotactic radiosurgery, or enucleation~* Karnofsky performance status (KPS) \>= 70 or Eastern Cooperative Oncology Group (ECOG)~* Total bilirubin \< 1.5 mg/dl~* Aspartate transaminase (AST) up to two times normal limit~* Alanine transaminase (ALT) up to two times normal limit~* Creatinine \< 2.0 mg/dl~* Functional left kidney based on computed tomography (CT) imaging~* Positron emission tomography (PET)/CT demonstrating no evidence of metastatic disease~* If a woman is of childbearing potential, a negative serum pregnancy test must be documented; women of childbearing potential must agree to use contraception for the duration of radiation therapy (approximately 3 weeks)~* Understands the trial and procedures and is willing and able to sign the Informed Consent Form~Exclusion Criteria:~* Previous malignancy, other than localized cutaneous squamous cell carcinoma or basal cell carcinoma~* History of prior irradiation to the thorax or abdomen~* Inadequate hepatic or kidney function (as specified above)~* Active peptic ulcer disease~* Upper gastrointestinal bleeding~* Pregnant women or women that refuse to use contraception throughout the entire study period~* Currently receiving chemotherapy~* Refuses to sign the informed consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (external beam radiation therapy) (Type: EXPERIMENTAL): Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).